Skip to main content
Top
Gepubliceerd in: Huisarts en wetenschap 11/2006

01-11-2006 | Onderzoek

Stoppen van onderhoudsbehandeling met inhalatiesteroïden bij COPD

Auteurs: dr. TRJ Schermer, NH Chavannes, AJC Hendriks, PNR Dekhuijzen, EFM Wouters, H van den Hoogen, CP van Schayck, C van Weel

Gepubliceerd in: Huisarts en wetenschap | Uitgave 11/2006

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Schermer TRJ, Chavannes NH, Hendriks AJC, Dekhuijzen PNR, Wouters EFM, Van den Hoogen H, Van Schayck CP, Van Weel C. Stoppen van onderhoudsbehandeling met inhalatiesteroïden bij COPD. Huisarts Wet 2006;49(11):544-9. Doel (1) De kans op een negatieve respiratoire uitkomst te bepalen na het stoppen van een onderhoudsbehandeling met inhalatiesteroïden bij eerstelijnspatiënten met chronisch obstructief longlijden (COPD) en (2) na te gaan of die kans verband houdt met patiëntkenmerken.Methode Prospectief open stoponderzoek in 45 huisartsenpraktijken bij 201 patiënten met lichte tot ernstige COPD die een onderhoudsbehandeling met inhalatiesteroïden ontvingen. De onderzochte effectmaten waren de kans op, en tijd tot,een negatieve respiratoire uitkomst (dat wil zeggen exacerbatie of aanhoudende toename van de luchtwegklachten) na het discontinueren van de inhalatiesteroïden.Resultaten De gemiddelde leeftijd van de deelnemende patiënten was 60,6 (SD 9,5) jaar, de postbronchodilatatoire FEV1 was 65,6% (SD 15,7) van de voorspelde waarde. De totale kans op een negatieve respiratoire uitkomst na het stoppen met de inhalatiesteroïden was 0,37 (95%-BI 0,31-0,44). Multivariate survivalanalyse liet zien dat leeftijd, geslacht, rookstatus en reversibiliteit van de luchtwegobstructie onafhankelijke voorspellers zijn van een negatieve respiratoire uitkomst. Voor vrouwen was het gecorrigeerde risico (hazardratio) 2,14 (95%-BI 1,31-3,50), vergeleken met mannen. Voor leeftijd was de hazardratio 1,05 (95%-BI 1,02-1,08) per levensjaar.Conclusie Het staken van een onderhoudsbehandeling met inhalatiesteroïden vergroot de kans op een exacerbatie of toename van luchtwegklachten aanzienlijk. Leeftijd, geslacht, rookstatus en reversibiliteit van de luchtwegobstructie zijn daarop mede van invloed. Als men overweegt om een COPD-patiënt te laten stoppen met inhalatiesteroïden, is het aan te bevelen vooraf een gedegen inschatting te maken van de kans op een negatieve uitkomst, en vroege uitingen daarvan zorgvuldig te monitoren.
Literatuur
go back to reference Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind placebo controlled study of fluticasone propionate in patiens with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. BMJ 2000;320:1297-303.CrossRef Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind placebo controlled study of fluticasone propionate in patiens with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. BMJ 2000;320:1297-303.CrossRef
go back to reference Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999;340:1948-53.CrossRef Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999;340:1948-53.CrossRef
go back to reference Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 1999;353:1819-23.CrossRef Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 1999;353:1819-23.CrossRef
go back to reference Wise MD, Connet J, Weinmann G, Scanlon P, Skeans M. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-9.CrossRef Wise MD, Connet J, Weinmann G, Scanlon P, Skeans M. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-9.CrossRef
go back to reference Sutherland ER, Allmers H, Ayas NT, Venn AJ, Martin RJ. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: A meta-analysis. Thorax 2003;58:937-41.CrossRef Sutherland ER, Allmers H, Ayas NT, Venn AJ, Martin RJ. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: A meta-analysis. Thorax 2003;58:937-41.CrossRef
go back to reference Highland KB, Strange C, Heffner JE. Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease: A meta-analysis. Ann Intern Med 2003;138:969-73.CrossRef Highland KB, Strange C, Heffner JE. Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease: A meta-analysis. Ann Intern Med 2003;138:969-73.CrossRef
go back to reference Geijer RMM, Van Schayck CP, Van Weel C, Sachs AP, Bottema BJAM, Smeele IJM, et al. NHG-Standaard COPD: Behandeling. Huisarts Wet 2001;44:207-19. Geijer RMM, Van Schayck CP, Van Weel C, Sachs AP, Bottema BJAM, Smeele IJM, et al. NHG-Standaard COPD: Behandeling. Huisarts Wet 2001;44:207-19.
go back to reference Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46.CrossRef Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46.CrossRef
go back to reference National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59 Suppl 1:1-232. National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59 Suppl 1:1-232.
go back to reference Jackevicius CA, Chapman KR. Prevalence of inhaled corticosteroid use among patients with chronic obstructive pulmonary disease: A survey. Ann Pharmacother 1997;31:160-4.CrossRef Jackevicius CA, Chapman KR. Prevalence of inhaled corticosteroid use among patients with chronic obstructive pulmonary disease: A survey. Ann Pharmacother 1997;31:160-4.CrossRef
go back to reference Roche N, Lepage T, Bourcereau J, Terrioux P. Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease. Eur Respir J 2001;18:903-8.CrossRef Roche N, Lepage T, Bourcereau J, Terrioux P. Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease. Eur Respir J 2001;18:903-8.CrossRef
go back to reference Jarad NA, Wedzicha JA, Burge PS, Calverley PMA. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. Respir Med 1999;93:161-6.CrossRef Jarad NA, Wedzicha JA, Burge PS, Calverley PMA. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. Respir Med 1999;93:161-6.CrossRef
go back to reference O’Brien A, Russo-Magno P, Karki A, Hiranniramol S, Hardin M, Kaszuba M, et al. Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. Am J Respir Crit Care Med 2001;164;365-71.CrossRef O’Brien A, Russo-Magno P, Karki A, Hiranniramol S, Hardin M, Kaszuba M, et al. Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. Am J Respir Crit Care Med 2001;164;365-71.CrossRef
go back to reference Van der Valk P, Monninkhof E, Van der Palen J, Zielhuis G, Van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: The COPE study. Am J Respir Crit Care Med 2002;166:1358-63.CrossRef Van der Valk P, Monninkhof E, Van der Palen J, Zielhuis G, Van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: The COPE study. Am J Respir Crit Care Med 2002;166:1358-63.CrossRef
go back to reference Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005;60:480-7.CrossRef Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005;60:480-7.CrossRef
go back to reference Van der Palen J, Monninkhof E, Van der Valk P, Sullivan SD, Veenstra DL. Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease. Thorax 2006;61:29-33.CrossRef Van der Palen J, Monninkhof E, Van der Valk P, Sullivan SD, Veenstra DL. Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease. Thorax 2006;61:29-33.CrossRef
go back to reference Chavannes NH, Schermer TRJ, Wouters EF, Van Weel C, Van Schayck CP. Treatment of COPD in general practice: the COOPT study. Eur Respir J 2001;18 Suppl 33:348s. Chavannes NH, Schermer TRJ, Wouters EF, Van Weel C, Van Schayck CP. Treatment of COPD in general practice: the COOPT study. Eur Respir J 2001;18 Suppl 33:348s.
go back to reference Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995;8:1398-420.CrossRef Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995;8:1398-420.CrossRef
go back to reference Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. [Lung volumes and forced ventilatory flows. Work Group on Standardization of Respiratory Function Tests. European Community for Coal and Steel. Official position of the European Respiratory Society]. Rev Mal Respir 1994;11 Suppl 3:5-40.PubMed Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. [Lung volumes and forced ventilatory flows. Work Group on Standardization of Respiratory Function Tests. European Community for Coal and Steel. Official position of the European Respiratory Society]. Rev Mal Respir 1994;11 Suppl 3:5-40.PubMed
go back to reference Collett D. Modelling survival data in medical research. London: Chapman and Hall, 1994.CrossRef Collett D. Modelling survival data in medical research. London: Chapman and Hall, 1994.CrossRef
go back to reference Tirimanna PR, Van Schayck CP, Den Otter JJ, Van Weel C, Van Herwaarden CL, Van den Boom G, et al. Prevalence of asthma and COPD in general practice in 1992: Has it changed since 1977? Br J Gen Pract 1996;46:277-81.PubMedPubMedCentral Tirimanna PR, Van Schayck CP, Den Otter JJ, Van Weel C, Van Herwaarden CL, Van den Boom G, et al. Prevalence of asthma and COPD in general practice in 1992: Has it changed since 1977? Br J Gen Pract 1996;46:277-81.PubMedPubMedCentral
go back to reference Van den Boom G, Van Schayck CP, Van Mollen MP, Tirimanna PR, Den Otter JJ, Van Grunsven PM, et al. Active detection of chronic obstructive pulmonary disease and asthma in the general population: Results and economic consequences of the DIMCA program. Am J Respir Crit Care Med 1998;158:1730-8.CrossRef Van den Boom G, Van Schayck CP, Van Mollen MP, Tirimanna PR, Den Otter JJ, Van Grunsven PM, et al. Active detection of chronic obstructive pulmonary disease and asthma in the general population: Results and economic consequences of the DIMCA program. Am J Respir Crit Care Med 1998;158:1730-8.CrossRef
go back to reference American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77-S120. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77-S120.
go back to reference Van Schayck CP, Dekhuijzen PN, Gorgels WJ, Van Grunsven PM, Molema J, Van Herwaarden CL, et al. Are anti-oxidant and anti-inflammatory treatments effective in different subgroups of COPD? A hypothesis. Respir Med 1998;92:1259-64.CrossRef Van Schayck CP, Dekhuijzen PN, Gorgels WJ, Van Grunsven PM, Molema J, Van Herwaarden CL, et al. Are anti-oxidant and anti-inflammatory treatments effective in different subgroups of COPD? A hypothesis. Respir Med 1998;92:1259-64.CrossRef
go back to reference Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003;21:68-73.CrossRef Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003;21:68-73.CrossRef
go back to reference Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004;23:698-702.CrossRef Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004;23:698-702.CrossRef
go back to reference Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52.CrossRef Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52.CrossRef
Metagegevens
Titel
Stoppen van onderhoudsbehandeling met inhalatiesteroïden bij COPD
Auteurs
dr. TRJ Schermer
NH Chavannes
AJC Hendriks
PNR Dekhuijzen
EFM Wouters
H van den Hoogen
CP van Schayck
C van Weel
Publicatiedatum
01-11-2006
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Huisarts en wetenschap / Uitgave 11/2006
Print ISSN: 0018-7070
Elektronisch ISSN: 1876-5912
DOI
https://doi.org/10.1007/BF03084930

Andere artikelen Uitgave 11/2006

Huisarts en wetenschap 11/2006 Naar de uitgave